Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma.

@article{Pellicelli2014LongTN,
  title={Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma.},
  author={Adriano Maria Pellicelli and Pascal Vignally and Vincenzo Messina and Antonio Izzi and Ettore Mazzoni and Angelo Barlattani and Donato Bacca and Mario Romano and Fabrizio Mecenate and Tommaso Stroffolini and Caterina Furlan and Antonio Picardi and Umberto Vespasiani Gentilucci and Roberto Gulminetti and Maria Elena Bonaventura and Roberto Villani and Cecilia D'Ambrosio and Amerigo Paffetti and Cristina Mastropietro and Massimo Marignani and Lucia Fondacaro and Giuseppe Cerasari and Arnaldo Andreoli and Giorgio Barbarini},
  journal={Annals of hepatology},
  year={2014},
  volume={13 4},
  pages={
          376-85
        }
}
UNLABELLED BACKGROUND AND RATIONALE OF THE STUDY: Effect of Long-term nucleoside/nucleotide (NUC) on hepatocellular carcinoma (HCC) incidence in a population of HBeAg-negative genotype D patients has not been adequately studied in real-life cohorts. Our aim was to evaluate the impact of liver fibrosis and other variables on HCC incidence in this population of patients. Of 745 patients with chronic hepatitis B (CHB), 306 HBeAg-negative genotype D were selected and included in this study. All… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 21 REFERENCES

The clinical implications of hepatitis B virus genotype: recent advances

LL Chih, K. Jia-Horng
  • J Gastroenterol Hepatol
  • 2011